4-氨基-8-甲基喹啉 | 893762-15-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氨基-8-甲基喹啉
• 英文名称: 8-methylquinolin-4-amine
• CAS: 893762-15-7
• 化学式: C₁₀H₁₀N₂
• mdl: MFCD07644577
• 分子量: 158.203
• InChiKey: TVZPXEZTWRAIID-UHFFFAOYSA-N

物化性质

• 沸点：
  345.0±27.0 °C(Predicted)
• 密度：
  1.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933499090
• WGK Germany：
  3

反应信息

• 作为产物：
  描述：

  4-氯-8-甲基喹啉 在 hexaamminenickel (II) chloride 、 4,4'-二甲基-2,2'-联吡啶 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 以88 %的产率得到4-氨基-8-甲基喹啉
  参考文献：
  名称：

  沃纳盐作为镍和氨源用于光化学合成芳基伯胺

  摘要：

  Werner 盐 [Ni(NH 3 ) 6 ]Cl 2可用作氮源和催化镍源，在催化量的联吡啶配体存在下，在 390– 的照射下，可以有效地胺化芳基氯。 395 nm光无需任何额外的催化剂，解决了过渡金属镍催化剂易失活和难以回收的问题。

  DOI：

  10.1002/anie.202314355

文献信息

• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143143A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• [EN] TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS.<br/>[FR] DÉRIVÉS DE TRIAZOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA TANKYRASE
  申请人：GOLDING LOUISE

  公开号：WO2022008896A1

  公开（公告）日：2022-01-13

  The present invention relates to compounds of general formula (I), tautomers, stereoisomers, N-oxides, pharmaceutically acceptable salts and pro-drug thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy: wherein: a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -N(R)2, and -SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); Y represents: an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); a 5- or 6-membered, saturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or a C3-6 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); and Z represents: an aryl group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -OH, -N(R' )2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and -C(0)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); or an unsaturated, 5- to 10-membered mono- or bicyclic heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), -CN, -NO2, -OH, -N(R')2 (where each R1 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2R2 (where R2 is H or C1-6 alkyl, e.g. H or C1-3 alkyl), -SO2N(R3)2 (where each R3 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl), and -C(O)N(R4)2 (where each R4 is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl, or wherein both R4 groups, together with the intervening nitrogen atom, form a 3 to 6 membered saturated heterocyclic ring); with the proviso: that when the compound is other than an N-oxide of formula (I), Z must be substituted by at least one substituent selected from -OH, -N(R3)2, -SO2N(R3)2 and -C(O)N(R4)2, preferably by at least one substituent selected from -OH, -SO2N(R3)2 and -C(O)N(R4)2. These compounds find particular use in the treatment and/or prevention of a disease or disorder responsive to inhibition of tankyrase 1 and/or 2, for example a disorder which is mediated by tankyrase 1 and/or 2 such as cancer.

  本发明涉及一般式(I)的化合物、互变异构体、立体异构体、N-氧化物、药学上可接受的盐及其前药，以及制备这些化合物的方法、含有这些化合物的制剂的制备方法以及它们在治疗中的应用：其中：虚线表示可选键；X表示：一个5-或6-成员的不饱和杂环基，可选地被一个或多个（例如1、2或3个）取代基独立地选自卤素（即F、Cl、Br、I）、C1-6烷基（例如C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）、C1-6烷氧基（例如C1-3烷氧基）、-CN、-NO2、-N（R）2和-SO2R（其中每个R独立地为H或C1-6烷基，例如H或C1-3烷基）；一个可选地被一个或多个（例如1或2个）取代基独立地选自C1-6烷基（优选为C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）和C1-6烷氧基（例如C1-3烷氧基）的C3-5环烷基；或一个可选地被一个或多个（例如1、2或3个）取代基独立地选自卤素（即F、Cl、Br、I）、C1-6烷基（例如C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）和C1-6烷氧基（例如C1-3烷氧基）的芳基基团；Y表示：一个可选地被一个或多个（例如1、2或3个）取代基独立地选自卤素（即F、Cl、Br、I）、C1-6烷基（例如C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）和C1-6烷氧基（例如C1-3烷氧基）的芳基或杂环芳基基团；一个可选地被一个或多个（例如1、2或3个）取代基独立地选自C1-6烷基（优选为C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）和C1-6烷氧基（例如C1-3烷氧基）的5-或6-成员饱和杂环基；或一个可选地被一个或多个（例如1或2个）取代基独立地选自C1-6烷基（优选为C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）和C1-6烷氧基（例如C1-3烷氧基）的C3-6环烷基；Z表示：一个可选地被一个或多个（例如1、2或3个）取代基独立地选自卤素（即F、Cl、Br、I）、C1-6烷基（例如C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）、C1-6烷氧基（例如C1-3烷氧基）、-CN、-NO2、-OH、-N（R'）2（其中每个R1独立地为H或C1-6烷基，例如H或C1-3烷基）、-SO2R2（其中R2为H或C1-6烷基，例如H或C1-3烷基）、-SO2N（R3）2（其中每个R3独立地为H或C1-6烷基，例如H或C1-3烷基）和-C（0）N（R4）2（其中每个R4独立地为H或C1-6烷基，例如H或C1-3烷基，或其中两个R4基与介于其间的氮原子一起形成3到6成员的饱和杂环环）；或一个可选地被一个或多个（例如1、2或3个）取代基独立地选自卤素（即F、Cl、Br、I）、C1-6烷基（例如C1-3烷基）、C1-6卤代烷基（例如C1-3卤代烷基）、C1-6烷氧基（例如C1-3烷氧基）、-CN、-NO2、-OH、-N（R'）2（其中每个R1独立地为H或C1-6烷基，例如H或C1-3烷基）、-SO2R2（其中R2为H或C1-6烷基，例如H或C1-3烷基）、-SO2N（R3）2（其中每个R3独立地为H或C1-6烷基，例如H或C1-3烷基）和-C（O）N（R4）2（其中每个R4独立地为H或C1-6烷基，例如H或C1-3烷基，或其中两个R4基与介于其间的氮原子一起形成3到6成员的饱和杂环环）的不饱和的5-到10-成员的单环或双环杂环基；但是，当化合物不是式(I)的N-氧化物时，Z必须被至少一个取代基取代，所述取代基选自-OH、-N（R3）2、-SO2N（R3）2和-C（O）N（R4）2，优选地被至少一个取代基选自-OH、-SO2N（R3）2和-C（O）N（R4）2。这些化合物在治疗和/或预防对坦克酰酶1和/或2的抑制有反应的疾病或障碍中特别有用，例如由坦克酰酶1和/或2介导的癌症。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。